NEW YORK & CALIFORNIA, UNITED STATES – Accenture, a global leader in outsourcing and professional services, has made a significant investment in Earli Inc., a biotechnology company pioneering innovative methods for early cancer detection.
The investment was made through Accenture Ventures, though financial terms were not disclosed.
Based in Redwood City, California, Earli aims to transform cancer care by addressing one of oncology’s biggest challenges: accurately distinguishing between healthy and cancerous cells.
Their groundbreaking technology uses programmable genetic constructs to detect cancer cells early, enabling quicker diagnosis and more personalized treatments.
Improving cancer detection and treatment
Earli’s “synthetic biopsy” approach enhances the sensitivity and specificity of cancer detection. This method allows for the earlier diagnosis of cancer, offering pharmaceutical and biotech companies the ability to develop personalized treatments more rapidly and at a reduced cost.
Dr. Petra Jantzer, senior managing director and global lead of Accenture Life Sciences, highlighted the impact of this technology, stating, “Earli’s synthetic biopsy method is a step change in early cancer detection technologies and will offer significant advantages to biopharma companies by improving the precision and efficacy of new treatments and diagnostics.”
Expanding collaboration in the biotech field
The partnership with Accenture will enable Earli to expand its collaborations with global health and pharma companies. These partnerships are critical, as early detection and treatment are key to improving cancer survival rates.
Earli’s non-invasive screening techniques, including blood samples and PET scans, have the potential to detect multiple types of cancer, even those too small for current methods to find.
Cyriac Roeding, co-founder and CEO of Earli, expressed enthusiasm about the partnership, saying, “Accenture’s impressive network of biopharma clients will be very impactful for Earli. It is fantastic to have Accenture support our mission to make cancer a benign experience.”
Earli joins Accenture Ventures’ Project Spotlight, an initiative that supports startups developing disruptive enterprise technologies. Other biotechnology companies in the program include Turbine, QuantHealth, Virtonomy, and Ocean Genomics.
